- Stocks
- Healthcare
- NASDAQ: ABMD

Price (delayed)

$285.92

Market cap

$12.93B

P/E Ratio

64.4

Dividend/share

N/A

EPS

$4.44

Enterprise value

$12.75B

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has

Abiomed's equity has increased by 20% YoY and by 7% from the previous quarter

ABMD's P/E is 19% below its 5-year quarterly average of 79.5 but 10% above its last 4 quarters average of 58.6

ABMD's quick ratio is down by 18% since the previous quarter but it is up by 15% year-on-year

The net income has contracted by 18% YoY and by 3.5% from the previous quarter

ABMD's EPS is down by 18% year-on-year and by 3.5% since the previous quarter

What are the main financial stats of ABMD

Market
Valuations
Earnings

Shares outstanding

45.23M

Market cap

$12.93B

Enterprise value

$12.75B

Price to earnings (P/E)

64.4

Price to book (P/B)

10.24

Price to sales (P/S)

15.9

EV/EBIT

50.19

EV/EBITDA

45.98

EV/Sales

15.69

Revenue

$812.94M

EBIT

$254.04M

EBITDA

$277.31M

Free cash flow

$236.88M

Per share
Balance sheet
Liquidity

EPS

$4.44

Free cash flow per share

$5.24

Book value per share

$27.91

Revenue per share

$17.98

TBVPS

$28.88

Total assets

$1.43B

Total liabilities

$166.99M

Debt

$0

Equity

$1.26B

Working capital

$573.29M

Debt to equity

0

Current ratio

5.76

Quick ratio

4.81

Net debt/EBITDA

-0.65

Margins
Efficiency
Dividend

EBITDA margin

34.1%

Gross margin

80.9%

Net margin

24.7%

Operating margin

27.7%

Return on assets

15.4%

Return on equity

17.4%

Return on invested capital

27.9%

Return on capital employed

19.4%

Return on sales

31.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Abiomed stock price performed over time

Intraday

-5.08%

1 week

-11.82%

1 month

-12.26%

1 year

82.02%

YTD

-11.81%

QTD

-11.81%

How have Abiomed's revenue and profit performed over time

Revenue

$812.94M

Gross profit

$657.74M

Operating income

$224.81M

Net income

$200.47M

Gross margin

80.9%

Net margin

24.7%

The net income has contracted by 18% YoY and by 3.5% from the previous quarter

ABMD's net margin is down by 15% year-on-year and by 4.6% since the previous quarter

The company's operating income fell by 12% YoY

Abiomed's operating margin has decreased by 9% YoY

What is Abiomed's growth rate over time

What is Abiomed stock price valuation

P/E

64.4

P/B

10.24

P/S

15.9

EV/EBIT

50.19

EV/EBITDA

45.98

EV/Sales

15.69

ABMD's P/E is 19% below its 5-year quarterly average of 79.5 but 10% above its last 4 quarters average of 58.6

ABMD's EPS is down by 18% year-on-year and by 3.5% since the previous quarter

ABMD's P/B is 22% below its 5-year quarterly average of 13.2 but 8% above its last 4 quarters average of 9.5

Abiomed's equity has increased by 20% YoY and by 7% from the previous quarter

The price to sales (P/S) is 15% higher than the last 4 quarters average of 13.8

The company's revenue fell by 3.4% YoY

How efficient is Abiomed business performance

ABMD's return on equity is down by 30% year-on-year and by 8% since the previous quarter

Abiomed's ROA has decreased by 29% YoY and by 8% from the previous quarter

The ROIC has contracted by 24% YoY and by 8% from the previous quarter

ABMD's return on sales is down by 17% year-on-year and by 7% since the previous quarter

What is ABMD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ABMD.

How did Abiomed financials performed over time

Abiomed's total assets has increased by 19% YoY and by 8% from the previous quarter

ABMD's quick ratio is down by 18% since the previous quarter but it is up by 15% year-on-year

ABMD's debt is 100% smaller than its equity

Abiomed's equity has increased by 20% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.